<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: [(18)F]-fluorodeoxyglucose-<z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (FDG-PET) images are usually quantitatively analyzed in "whole-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>" volumes of interest </plain></SENT>
<SENT sid="1" pm="."><plain>Also parameters determined with dynamic PET acquisitions, such as the Patlak <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolic rate (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>(<z:chebi fb="0" ids="17234">glc</z:chebi>)) and pharmacokinetic rate constants of two-tissue compartment modeling, are most often derived per lesion </plain></SENT>
<SENT sid="2" pm="."><plain>We propose segmentation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> to determine <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, potentially useful for dose-painting in radiotherapy and elucidating mechanisms of FDG uptake </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND MATERIALS: In 41 patients with 104 lesions, dynamic FDG-PET was performed </plain></SENT>
<SENT sid="4" pm="."><plain>On <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>(<z:chebi fb="0" ids="17234">glc</z:chebi>) images, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were segmented in quartiles of background subtracted maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>(<z:chebi fb="0" ids="17234">glc</z:chebi>) (0%-25%, 25%-50%, 50%-75%, and 75%-100%) </plain></SENT>
<SENT sid="5" pm="."><plain>Pharmacokinetic analysis was performed using an irreversible two-tissue compartment model in the three segments with highest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>(<z:chebi fb="0" ids="17234">glc</z:chebi>) to determine the rate constants of FDG metabolism </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: From the highest to the lowest quartile, significant decreases of uptake (K(1)), washout (k(2)), and phosphorylation (k(3)) rate constants were seen with significant increases in tissue blood volume fraction (V(b)) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> regions with highest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>(<z:chebi fb="0" ids="17234">glc</z:chebi>) are characterized by high cellular uptake and phosphorylation rate constants with relatively low blood volume fractions </plain></SENT>
<SENT sid="8" pm="."><plain>In regions with less metabolic activity, the blood volume fraction increases and cellular uptake, washout, and phosphorylation rate constants decrease </plain></SENT>
<SENT sid="9" pm="."><plain>These results support the hypothesis that regional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:chebi fb="105" ids="17234">glucose</z:chebi> phosphorylation rate is not dependent on the transport of nutrients (i.e., FDG) to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>